



University of Colorado Health Sciences Center
School of Medicine · Department of Pediatrics

Infectious Diseases

Affiliated with
The Children's Hospital

Pediatrics | Pediatrics Home | Clinical Services | Research | Education | Subspecialties, Related Programs & Affiliates | Faculty | UCHSC Home

Search



Research Funding

(listed alphabetically by Principal Investigator)

[Subspecialties,
Related Programs &
Affiliates](#)

[Infectious Diseases](#)

[Home](#)

◦ [Clinical Services](#)

◦ [Research](#)

◦ [Research Funding](#)

◦ [Education](#)

◦ [Fellowship](#)

◦ [Faculty](#)

◦ [Awards and Honors](#)

◦ [Publications](#)

[Pediatrics Home](#)

[School of Medicine](#)

[UCHSC Home](#)

[The Children's](#)

[Hospital](#)

2003-2004

A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril (VP63843) in the Treatment of Neonates with EV Sepsis Syndrome (Protocol Version 2.0/Version Date 4/25/99)

Principal Investigator: Mark J. Abzug, MD

Source: National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group, National Institutes of Health

Amount: Per patient enrolled

Term: 1999-ongoing

Safety of Ciprofloxacin in Pediatric Patients

Principal Investigator: Marsha S. Anderson, MD

Source: Bayer Corporation

Amount: Per patient

Term: 2001-present

Denver for Advanced Public Health Preparedness Center

Principal Investigator: Arthur Davidson, MD

Co-Investigator: Marsha S. Anderson, MD

Source: Centers for Disease Control and Prevention - U90/CCU817608

Amount: \$12,000

Term: 2000-2003

Apoptotic Signaling in Viral Myocarditis

Principal Investigator: Roberta L. DeBiasi, MD

Source: National Institutes of Health Physician Scientist Award - 1 K08 A152261-01

Amount: \$604,800

Term: 2002-2007

Effectiveness of Pneumococcal Conjugate Vaccine in Children

Co-Principal Investigators: Mary P. Glodé, MD, and Ann-Christine Nyquist, MD, MSPH

Source: Centers for Disease Control and Prevention - 2890

Amount: \$419,460

Term: 2000-2004

Pertussis Vaccine Effectiveness Study Among Children Aged 6 to 59 Months

Co-Principal Investigators: Mary P. Glodé, MD, and Christine Robinson, PhD

Source: Centers for Disease Control and Prevention - 98B066(N)

Amount: \$148,300

Term: 1998-2003

A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of Bd-Alum/MPL Vaccine in the Prevention of Genital Herpes Diseases in Young Women Who Are HSV-1 and -2 Seronegative

Principal Investigator: Myron J. Levin, MD

Source: National Institute of Allergy and Infectious Disease and St. Louis University/GlaxoSmithKline

Amount: \$974,693/yr

Term: 2002-2006

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Pilot Study to Assess the Safety of Live, Attenuated Varicella-Zoster Vaccine Given Concomitantly with Recombinant Human Interleukin-12 (rhIL-12) in Healthy Adults 60 to 79 Years of Age

Principal Investigator: Myron J. Levin, MD

Source: Genetics Institute

Amount: \$9,126,000

Term: 1999-2004

University of Colorado Center for AIDS Research

Principal Investigator: Robert Schooley, MD

Co-Principal Investigator: Myron J. Levin, MD

Source: National Institute of Allergy and Infectious Disease

Amount: \$7,946,900

Term: 2003-2008

Study of the Safety and Efficacy of an Iontophoretic Device to Treat Recurrent Herpes Labialis

Principal Investigator: Myron J. Levin, MD

Source: Klearsen Corporation

Amount: \$7,946,900

Term: 2003-2005

Pediatric and Perinatal HIV Clinical Trials

Principal Investigator: Myron J. Levin, MD

Co-Investigator: Elizabeth J. McFarland, MD

Source: Westat and National Institutes of Health, National Institute of Child and Human Development - N01-HD-3-3162

Amount: \$5,010,161

Term: 2002-2007

Demonstration Project to Improve Research and Care of HIV-Infected Children

Principal Investigator: Myron J. Levin, MD

Co-Investigator: Elizabeth J. McFarland, MD

Source: Department of Health and Human Services, Health Resources and Services Administration, Ryan White Title IV HIV Program

Amount: \$4,437,722

Term: 1995-2004

Expansion of Pediatric ACTU

Principal Investigator: Myron J. Levin, MD

Co-Investigator: Adriana Weinberg, MD

Source: National Institute of Childhood Diseases - U0132915-05

Amount: \$4,156,500

Term: 1996-2007

Demonstration Project to Improve Research and Care of HIV-Infected Children

Principal Investigator: Myron J. Levin, MD

Co-Investigator: Elizabeth J. McFarland, MD

Source: Health Resources and Services Administration, Ryan White Title IV HIV Program

Amount: \$2,507,595

Term: 2001-2004

Trial of Varicella Vaccine for the Prevention of Herpes Zoster and its Complications

Principal Investigator: Myron J. Levin, MD

Source: National Institute of Allergy and Infectious Disease, Veterans Administration - VA CSP403

Amount: \$1,532,185

Term: 1998-2004

Depression and Trial of Varicella Vaccine in the Elderly

Principal Investigator: Myron J. Levin, MD

Source: UCLA Medical Center

Amount: \$388,001

Term: 2000-2004

Probe Study to Evaluate the Safety, Tolerability and Immunogenicity of a Process Upgrade Varicella-Zoster Vaccine as a Booster Dose in Previously Vaccinated Adults 60 Years of Age and Older

Principal Investigator: Myron J. Levin, MD

Source: Merck Research Laboratories - Zoster Protocol 005

Amount: \$132,000

Term: 1999-2004

Pediatric HIV Clinical Trials Network

Principal Investigator: Myron J. Levin, MD

Co-Investigator: Mark J. Abzug, MD

Source: National Institutes of Health, National Institute of Child Health and Human Development - N01-HD-3-3162

Amount: \$117,875

Term: 2002-2004

A Phase III, Open-Labeled, Randomized, Multicenter, Clinical Study of the Safety of a Primary Series of GlaxoSmithKline Biologicals' DTPa-HepB-IPV Candidate Vaccine

Coadministered with HibTITER[®] and Prevnar[®] to Healthy Infants at 2, 4, and 6 Months of Age as Compared to the

Separate Administration of Infanrix[®] + Engerix-B[®] + IPOL[®] + HibTITER[®] + Prevnar[®]

Principal Investigator: Myron J. Levin, MD

Source: GlaxoSmithKline Biologicals - 084

Amount: \$111,678

Term: 2001-2003

Retrospective Study That Would Evaluate Asthmatic Children Who Had Already Received Varivax[®] in the Past

Principal Investigator: Myron J. Levin, MD

Source: Merck Research Laboratories

Amount: \$69,000
Term: 2003-2006

A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety, Tolerability and Immunogenicity After One and Two Doses of PHN/Zoster Vaccine

Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories - Zoster Protocol 007
Amount: \$54,900
Term: 2001-2004

Phospholipases in the Pathogenesis of Mycobacterium Tuberculosis

Principal Investigator: Sarah K. Parker, MD
Source: National Institutes of Health - 1 K08 AI050646-04
Amount: \$560,000
Term: 2002-2007

CD40-CD154 Interactions in Cryptosporidial Immunity

Principal Investigator: Esther Ponnuraj, PhD
Source: National Institutes of Health - R-01- A140870-05
Amount: \$673,622
Term: 2002-2005

Respiratory Viral Infections in Filipino Children

Principal Investigator: Eric A. F. Simoes, MD
Co-Investigator: Adriana Weinberg, MD
Source: World Health Organization
Amount: \$170,000
Term: 2001-2004

Immunogenicity of Influenza Vaccine in Children with Rheumatologic Disorders

Principal Investigator: Jennifer Soep, MD
Co-Investigator: Adriana Weinberg, MD
Source: Pediatric General Clinical Research Center
Amount: \$10,000
Term: 2001-2003

Pediatric Pharmacology Research Unit Network

Principal Investigator: Stanley J. Szeffler, MD
Co-Principal Investigators: Harley A. Rotbart, MD, and Mark J. Abzug, MD
Co-Investigator: Joseph D. Spahn, MD
Source: National Institutes of Health, National Institute of Childhood Health and Disease - HD37237
Amount: \$1,364,175
Term: 1999-2003

Pediatric AIDS Clinical Trials Group

Principal Investigator: Adriana Weinberg, MD
Source: National Institute of Childhood Diseases - N01-HD-33162
Amount: \$1,796,322
Term: 1997-2003

Shingles Prevention Study

Principal Investigator: Adriana Weinberg, MD
Source: Veterans Administration - CSP403
Amount: \$960,642

Term: 2001-2004

Immune Responses to Varicella Vaccine in HIV-Infected Adults

Principal Investigator: Kathleen Brady, MD

Co-Investigator: Adriana Weinberg, MD

Source: National Institutes of Health - K23RR16116-02

Amount: \$754,246

Term: 2000-2005

Epidemiology of Adult Glioma

Principal Investigator: Margaret Wrensch, MD

Co-Investigator: Adriana Weinberg, MD

Source: National Institutes of Health - R01 CA52689

Amount: \$8,000,863

Term: 2001-2006

Manufacturing of VZV Antigen

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$280,000

Term: 1999-2004

VZV ELISPOT Validation for Studies of VZV-Specific Cell-Mediated Immunity

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$224,125

Term: 2001-2004

CMV Immune Reconstruction in AIDS Patients on HAART

Principal Investigator: Adriana Weinberg, MD

Source: National Institutes of Health - 2U01A38858 AACTG 360.06

Amount: \$152,000

Term: 2002-2003

Persistence of VZV Immunity in Elderly Recipients of the PHN/Zoster Vaccine

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$49,000

Term: 2001-2004

Cell-Mediated Immunity in Herpes Zoster Patients

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$48,000

Term: 2001-2004

Kinetics of Cell-Mediated Immune Responses to PHN/Zoster Vaccine

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$46,626

Term: 2001-2004

Diagnosis of CMV Infection in Stem Cell Recipients

Principal Investigator: Adriana Weinberg, MD

Source: AmCell

Amount: \$20,000

Term: 2002-2004

PCR Diagnosis of Zoster

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$15,000

Term: 2001-2003

Evaluation of Directigen EZ Flu A+B Kit

Principal Investigator: Adriana Weinberg, MD

Source: Becton Dickinson

Amount: \$10,000

Term: 2002-2003

Flu OIA Evaluation

Principal Investigator: Adriana Weinberg, MD

Source: Biostar

Amount: \$10,000

Term: 2002-2003

2001-2002

A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril (Vp63843) in the Treatment of Infants with Enteroviral Meningitis (Protocol Version 2.0)

Principal Investigator: Mark J. Abzug, MD

Source: National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group

Amount: Per patient enrolled

Term: 1999-2001

A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril (Vp63843) in the Treatment of Neonates with EV Sepsis Syndrome (Protocol Version 2.0/Version Date 4/25/99)

Principal Investigator: Mark J. Abzug, MD

Source: National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group

Amount: Per patient enrolled

Term: 1999-2002

A Double-Blind, Randomized, Placebo-Controlled Safety and Efficacy Trial of Suspension Formulation of Pleconaril in the Treatment of Viral Respiratory Infection in Children Age 2 to 12 Years (Protocol No. 843-051)

Principal Investigator: Mark J. Abzug, MD

Source: Viropharma

Amount: \$4,467

Term: 2000-2001

Natural History of Viral Meningitis in Young Children (4 to 7 Years of Age)

Principal Investigator: Mark J. Abzug, MD

Source: Viropharma

Term: 1999-2001

Safety of Ciprofloxacin in Pediatric Patients

Principal Investigator: Marsha S. Anderson, MD
Source: Bayer Corporation
Amount: Per patient
Term: 2001-2002

Immune Responses to Varicella Vaccine in HIV-Infected Adults

Principal Investigator: Kathleen Brady, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - K23RR16116-02
Amount: \$754,246
Term: 2000-2005

Denver for Advanced Public Health Preparedness Center

Principal Investigator: Arthur Davidson, MD
Co-Investigator: Marsha S. Anderson, MD
Source: Centers for Disease Control and Prevention - U90/CCU817608
Amount: \$12,000
Term: 2000-2003

Immunologic Aspects of the Pathogenesis of Chronic Sinusitis in Children: A Six-Month Pilot Study

Principal Investigator: Kenny Chan, MD
Co-Investigators: Andrew H. Liu, MD, and Mark J. Abzug, MD
Source: Pediatric General Clinical Research Center
Term: 1999-2001

Apoptotic Signaling in Viral Myocarditis

Principal Investigator: Roberta L. DeBiasi, MD
Source: National Institutes of Health Physician Scientist Award - 1 K08 A152261-01
Amount: \$604,800
Term: 2002-2007

Identification and Targeting of Apoptotic Signaling Pathways in Viral Myocarditis

Principal Investigator: Roberta L. DeBiasi, MD
Source: Veterans Administration Research Career Development Award
Amount: \$109,500
Term: 2002-2002

Infectious Diseases Society of American Young Investigator Award

Principal Investigator: Roberta L. DeBiasi, MD
Source: Ortho-McNeil Pharmaceuticals
Amount: \$80,000
Term: 2000-2002

Effectiveness of Pneumococcal Conjugate Vaccine in Children

Co-Principal Investigators: Mary P. Glodé, MD, and Ann-Christine Nyquist, MD, MSPH
Source: Centers for Disease Control and Prevention - 2890
Amount: \$419,460
Term: 2000-2003

Pertussis Vaccine Effectiveness Study Among Children Aged 6 to 59 Months

Co-Principal Investigators: Mary P. Glodé, MD, and Christine

Robinson, PhD

Source: Centers for Disease Control and Prevention - 98B066(N)

Amount: \$148,300

Term: 1998-2003

Trial of Varicella Zoster Vaccine for the Prevention of Herpes Zoster and Its Complications

Principal Investigator: Anthony R. Hayward, MD, PhD

Source: Merck Research Laboratories

Amount: Per protocol

Term: 1997-2002

A Comparison of the Safety, Tolerability and Immunogenicity of M-M-RTMII Manufactured with Recombinant Human Albumin (rHA) vs. M-M-RTMII Manufactured with Pooled-Donor Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age

Principal Investigator: Myron J. Levin, MD

Source: Merck Research Laboratories - Merck 009

Amount: \$92,605

Term: 2001-2002

A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate Safety, Tolerability and Immunogenicity After One and Two Doses of PHN/Zoster Vaccine

Principal Investigator: Myron J. Levin, MD

Source: Merck Research Laboratories - Zoster Study 007

Amount: \$54,900

Term: 2001-2002

A Phase III, Open-Labeled, Randomized, Multicenter, Clinical Study of the Safety of a Primary Series of GlaxoSmithKline's DTPa-HepB-IPV Candidate Vaccine Coadministered with HibTITER[®] and Prevnar[®] to Healthy Infants at 2, 4 and 6 Months of Age as Compared to the Separate Administration of Infanrix[®] + Engerix-B[®] + IPOL[®] + HibTITER[®] + Prevnar[®]

Principal Investigator: Myron J. Levin, MD

Source: GlaxoSmithKline - 084

Amount: \$111,678

Term: 2001-2003

A Phase 4, Open, Randomized, Controlled, Comparative, Multicenter US Study of the Safety of GlaxoSmithKline's Combination Hepatitis A and Hepatitis B Vaccine (Twinrix[®]) Administered on a 0, 1, 6 Month Schedule by Intramuscular Injection Compared with Concurrently Administered Monovalent Vaccines (Havrix[®]) in Healthy Adults 18 Years of Age and Older

Principal Investigator: Myron J. Levin, MD

Source: GlaxoSmithKline

Amount: \$168,085

Term: 2001-2002

A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valacyclovir for Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples

Principal Investigator: Myron J. Levin, MD

Source: GlaxoSmithKline - GSK 009

Amount: \$50,000
Term: 2001-2002

Expansion of Pediatric AIDS Clinical Trials Unit

Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institute of Child Health and Human Development - N01-HD-3-3162
Amount: \$21,715/yr
Term: 1995-2001

Expansion of Pediatric ACTU

Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institute of Childhood Diseases - U0132915-05
Amount: \$4,156,500
Term: 1996-2007

Demonstration Project to Improve Research and Care of HIV-Infected Children

Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Department of Health and Human Services, Health Resources and Services Administration, Ryan White Title IV HIV Program
Amount: \$2,507,595
Term: 2001-2004

Depression and Trial of Varicella Vaccine in the Elderly

Principal Investigator: Myron J. Levin, MD
Source: UCLA Medical Center
Amount: \$388,001
Term: 2000-2004

National Institute of Child Health and Human Development Pediatric and Perinatal HIV Clinical Trials

Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Westat, National Institute of Child Health and Human Development - No1-HD-3-3162
Amount: \$4,953,000
Term: 1996-2002

Probe Study to Evaluate the Safety, Tolerability and Immunogenicity of a Process Upgrade Varicella-Zoster Vaccine as a Booster Dose in Previously Vaccinated Adults 60 Years of Age and Older

Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories - 005 Booster
Amount: \$132,000
Term: 1999-2004

Ryan White Title IV HIV Program

Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institute of Child Health and Human Development - 5H 12 HA 00070-08
Amount: \$30,400/yr
Term: 1995-2001

Ryan White Title IV

Principal Investigator: Myron J. Levin, MD

Co-Investigator: Adriana Weinberg, MD

Source: Department of Health and Human Services, Health Resources and Services Administration - 2H 12 HA 00070-07

Amount: \$2,348,000

Term: 2001-2004

Trial of Varicella Vaccine for the Prevention of Herpes Zoster and its Complications (Protocol No. 403)

Principal Investigator: Myron J. Levin, MD

Source: National Institute of Allergy and Infectious Disease, Veterans Administration - VA CSP403

Amount: \$1,532,185

Term: 1998-2004

HIV Adherence Services Contract

Principal Investigator: Elizabeth J. McFarland, MD

Source: Colorado Department of Public Health and Environment

Amount: \$32,000

Term: 1999-2002

Mechanisms Leading to Decline of HIV-Specific CTL

Principal Investigator: Elizabeth J. McFarland, MD

Source: National Institutes of Health, National Institute of Allergy and Infectious Diseases - A1 45107

Amount: \$659,007

Term: 1998-2001

Children's Hospital Immunodeficiency Program, Ryan White Title I Formula Fund

Principal Investigator: Ann-Christine Nyquist, MD, MSPH

Source: Department of Health and Human Services, Health Resources and Services Administration, Ryan White Title I

Amount: \$64,422

Term: 2001-2002

Bile Duct Disease in CD154 Deficiency

Principal Investigator: Esther Ponnuraj, PhD

Source: March of Dimes Birth Defects Foundation - 6-FY99-427

Amount: \$50,000/yr

Term: 2001-2002

CD40-CD154 Interactions in Cryptosporidial Immunity

Principal Investigator: Esther Ponnuraj, PhD

Source: National Institutes of Health - R-21 A140870-04

Amount: \$188,750

Term: 2001-2002

CD40-CD154 Interactions in Cryptosporidial Immunity

Principal Investigator: Esther Ponnuraj, PhD

Source: National Institutes of Health - R-01- A140870-05

Amount: \$673,622

Term: 2002-2005

Respiratory Viral Infections in Filipino Children

Principal Investigator: Eric A. F. Simoes, MD

Co-Investigator: Adriana Weinberg, MD

Source: World Health Organization

Amount: \$170,000

Term: 2001-2004

Immunogenicity of Influenza Vaccine in Children with Rheumatologic Disorders

Principal Investigator: Jennifer Soep, MD

Co-Investigator: Adriana Weinberg, MD

Source: Pediatric General Clinical Research Center

Amount: \$10,000

Term: 2001-2003

Pediatric Pharmacology Research Unit Network

Principal Investigator: Stanley J. Szeffler, MD

Co-Principal Investigators: Harley A. Rotbart, MD, and Mark J.

Abzug, MD

Co-Investigator: Joseph D. Spahn, MD

Source: National Institutes of Health, National Institute of Childhood Health and Disease - HD37237

Amount: \$1,364,175

Term: 1999-2003

Reovirus-Induced Apoptosis: Veterans Administration Research Enrichment Award Fellow Program - Roberta L. DeBiasi, MD

Principal Investigator: Kenneth L. Tyler, MD

Source: Veterans Administration

Amount: \$50,000

Term: 1999-2001

Cell-Mediated Immunity in Herpes Zoster Patients

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$48,000

Term: 2001-2004

CMV Immune Reconstruction in AIDS Patients on HAART

Principal Investigator: Adriana Weinberg, MD

Source: National Institutes of Health - 2U01A38858 AACTG 360.06

Amount: \$152,000

Term: 2002-2003

CMV Immunology Laboratory

Principal Investigator: Adriana Weinberg, MD

Source: National Institutes of Health

Amount: \$18,120

Term: 1998-2001

Diagnosis of CMV Infection in Stem Cell Recipients

Principal Investigator: Adriana Weinberg, MD

Source: AmCell

Amount: \$20,000

Term: 2002-2004

Evaluation of Directigen EZ Flu A+B Kit

Principal Investigator: Adriana Weinberg, MD

Source: Becton Dickinson

Amount: \$10,000

Term: 2002-2003

Flu OIA Evaluation

Principal Investigator: Adriana Weinberg, MD

Source: Biostar

Amount: \$48,000

Term: 1999-2001

Flu OIA Evaluation

Principal Investigator: Adriana Weinberg, MD

Source: Biostar

Amount: \$10,000

Term: 2002-2003

In Vitro: Sensitivity of HSV Isolates from Patients Treated with Topical Penciclovir

Principal Investigator: Adriana Weinberg, MD

Source: SmithKline Beecham

Amount: \$112,430

Term: 1999-2001

Kinetics of Cell-Mediated Immune Responses to PHN/Zoster Vaccine

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$46,626

Term: 2001-2004

Manufacturing of VZV Antigen

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$280,000

Term: 1999-2004

Natural History of CMV Infection in AIDS Patients on HAART: Quantitative CMV PCR

Principal Investigator: Adriana Weinberg, MD

Source: National Institutes of Health, National Institute of Allergy and Infectious Disease - U01A38858 AACTG 27360.03

Amount: \$92,000

Term: 1999-2002

PCR Diagnosis of Herpes Zoster

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$10,000

Term: 1999-2001

PCR Diagnosis of Zoster

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$15,000

Term: 2001-2003

Pediatric AIDS Clinical Trials Group Immunology Core Laboratory

Principal Investigators: Adriana Weinberg, MD, and Elizabeth J. McFarland, MD

Source: National Institute of Child Health and Human Development

Amount: \$1,050,000

Term: 1997-2002

PACTG

Principal Investigator: Adriana Weinberg, MD

Source: National Institute of Childhood Diseases - N01-HD-33162

Amount: \$1,796,322

Term: 1997-2003

Persistence of VZV Immunity in Elderly Recipients of the PHN/Zoster Vaccine

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$49,000

Term: 2001-2004

Shingles Prevention Study

Principal Investigator: Adriana Weinberg, MD

Source: Veterans Administration - CSP403

Amount: \$960,642

Term: 2001-2004

VZV ELISPOT Validation for Studies of VZV-Specific Cell-Mediated Immunity

Principal Investigator: Adriana Weinberg, MD

Source: Merck Research Laboratories

Amount: \$224,125

Term: 2001-2004

Epidemiology of Adult Glioma

Principal Investigator: Margaret Wrensch, MD

Co-Investigator: Adriana Weinberg, MD

Source: National Institutes of Health - R01 CA52689

Amount: \$8,000,863

Term: 2001-2006

1999-2000

A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Infants with Enterovirus Meningitis

Principal Investigator: Mark J. Abzug, MD

Source: National Institutes of Health Collaborative Antiviral Study Group

Amount: Per patient enrolled

Term: May 1999-December 2001

A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Neonates with Enterovirus Sepsis Syndrome

Principal Investigator: Mark J. Abzug, MD

Source: National Institutes of Health Collaborative Antiviral Study Group

Amount: Per patient enrolled

Term: May 1999-December 2001

A Natural History Study of Neonates with Enteroviral Sepsis

Syndrome

Principal Investigator: Mark J. Abzug, MD

Source: Viropharma, Inc.

Amount: Per patient enrolled

Term: May 2000-December 2000

A Double-Blind, Randomized, Placebo-Controlled Evaluation of Pleconaril in the Prevention of Otitis Media in Children with a History of Otitis Media Following Picornavirus Respiratory Tract Infections

Co-Principal Investigator: Mark J. Abzug, MD

Co-Investigator: Candice Johnson, MD

Source: Viropharma, Inc.

Amount: \$2,490

Term: September 1998-December 1999

Randomized, Comparative, Dose-Ranging, Probe Study to Investigate the Safety and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine with a New Formulation of Serotype 6B

Co-Principal Investigator: Mark J. Abzug, MD

Co-Investigator: Candice E. Johnson, MD

Source: Merck Research Laboratories

Amount: \$33,040

Term: January 1998-September 1999

A Multicenter, Double Blind, Placebo Controlled Trial of Pleconaril in the Treatment of Enteroviral Meningitis in Children and Adolescents

Principal Investigator: Mark J. Abzug, MD

Source: Viropharma, Inc.

Amount: \$30,000

Term: May 1998-December 1999

A Multicenter, Double-Blind, Placebo-Controlled Trial of Pleconaril in the Treatment of Enteroviral Meningitis in Adolescents and Adults

Principal Investigator: Mark J. Abzug, MD

Source: Viropharma, Inc.

Amount: \$12,000

Term: May 1998-December 1999

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of Inhaled Zanamivir Treatment on Workplace Attendance and Healthcare Outcomes Due to Influenza A and B Infections

Principal Investigator: Mark J. Abzug, MD

Source: Glaxo Wellcome, Inc.

Amount: \$2,772

Term: January 1998-June 2000

Open-Label, Multicenter Trial to Evaluate the Safety and Immunogenicity of a Fifth Consecutive Dose (Booster) of CERTIVA in Healthy Children

Principal Investigator: Mark J. Abzug, MD

Source: North American Vaccine, Inc.

Amount: Per patient enrolled

Term: June 1998-December 2000

Evaluation of Safety and Immunogenicity of Tripedia in Children 4 to 6 Years of Age Who Have Received 4 Doses of Tripedia

Principal Investigator: Mark J. Abzug, MD

Source: Pasteur Merieux Connaught

Amount: \$15,840

Term: February 1998-December 2000

A Non-Drug Study to Evaluate Pain Assessment Tools in Young Children 4-7 Years of Age with Viral Meningitis

Principal Investigator: Mark J. Abzug, MD

Source: Viropharma, Inc.

Amount: Per patient enrolled

Term: August 1999-December 2000

Pathogenesis of Chronic Sinusitis in Children

Principal Investigator: Kenny Chan, MD

Co-Investigator: Mark J. Abzug, MD

Source: General Pediatric Clinical Research Center

Amount: \$13,740

Term: August 1998-February 1999

Immunologic Aspects of Pathogenesis of Chronic Sinusitis in Children: A 6-Month Pilot Study

Principal Investigator: Kenny Chan, MD

Co-Investigator: Mark J. Abzug, MD

Source: The Children's Hospital Research Institute and General Pediatric Clinical Research Center

Amount: \$28,590

Term: October 1999-September 2000

Safety and Efficacy of Valacyclovir in Immunocompromised Children with Herpes Zoster Infection, Multicenter Study

Principal Investigator: Marsha S. Anderson, MD

Source: Colorado Department of Health

Amount: Per patient enrolled

Term: 1999-2000

Investigation of the Mechanism of Cell Signaling in Neutrophils

Principal Investigator: Marsha S. Anderson, MD

Source: The Children's Hospital Research Institute

Amount: \$70,000

Term: 1999

Infectious Diseases Society of American Young Investigator Award

Principal Investigator: Roberta L. DeBiasi, MD

Source: Ortho-McNeil Pharmaceuticals

Amount: \$80,000

Term: July 2000-July 2002

Reovirus-Induced Apoptosis: Veterans Administration Research Enrichment Award Fellow Program - Roberta L. DeBiasi, MD

Principal Investigator: Kenneth L. Tyler, MD

Source: Veterans Administration

Amount: \$50,000

Term: July 1999-July 2001

Pertussis Vaccine Effectiveness Study Among Children Aged 6 to 59 Months

Principal Investigator: Mary P. Glodé, MD
Source: Centers for Disease Control and Prevention
Amount: \$148,320
Term: 1998-2001

Demonstration Project to Improve Research and Care of HIV-Infected Children

Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Health Resources and Services Administration, Ryan White Title IV HIV Program
Amount: \$1,390,897
Term: August 1995-July 2001

Assessment of the Ability of the Live Attenuated Oka/Merck Varicella Vaccine Made in the New Production Facility to Boost Immunity to Varicella in Adults 55 Years of Age and Older

Principal Investigator: Myron J. Levin, MD
Source: Merck Sharp and Dohme Research Laboratories
Amount: \$180,000
Term: November 1996-October 1999

Pilot Dose-Ranging Study to Assess the Safety and Tolerability of Live, Attenuated Oka/Merck Varicella-Zoster Vaccine in Healthy, Seropositive Adults 60 Years of Age and Older

Principal Investigator: Myron J. Levin, MD
Source: Merck Sharp and Dohme Research Laboratories
Amount: \$107,644
Term: November 1996-October 1999

Pilot Study to Assess the Ability of the Oka/Merck Varicella Vaccine to Boost Immunity to Varicella in Adults 55 Years of Age and Older. Additional Dose of Varicella to Boost CMI

Principal Investigator: Myron J. Levin, MD
Source: Merck Sharp and Dohme Research Laboratories
Amount: \$138,150
Term: November 1996-October 1999

Dose Response Study Comparing Varying Dosage Levels of Process Upgrade Varicella Vaccine (PUVV) in Concomitant Use with M-M-RTMII in Healthy Children

Principal Investigator: Myron J. Levin, MD
Source: Merck Sharp and Dohme Research Laboratories
Amount: \$52,700
Term: September 1998-February 1999

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) with MPL and its Efficacy to Prevent Genital Herpes Disease in Healthy HSV Positive or Negative Consorts of Subjects with Genital Herpes Disease

Principal Investigator: Myron J. Levin, MD
Source: SmithKline Beecham Biologicals
Amount: \$96,000

Term: July 1996-June 1999

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) with MPL to Prevent Genital Herpes Disease in Healthy Consorts of Subjects with Genital Herpes Disease

Principal Investigator: Myron J. Levin, MD

Source: SmithKline Beecham Biologicals

Amount: \$143,098

Term: July 1996-June 1999

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Pilot Study to Assess the Safety of Live, Attenuated Varicella-Zoster Vaccine Given Concomitantly with Recombinant Human Interleukin-12 (rhIL-12) in Healthy Adults 60 to 79 Years of Age

Principal Investigator: Myron J. Levin, MD

Source: Genetics Institute

Amount: \$96,000

Term: April 1998-March 1999

An Open Study in Healthy Subjects Who Experience Frequent Episodes of Herpes Labialis to Investigate Whether Repeated Treatment with Penciclovir Cream Leads to the Selection of Virus with Reduced Susceptibility to Penciclovir

Principal Investigator: Myron J. Levin, MD

Source: SmithKline Beecham Biologicals

Amount: \$177,912

Term: October 1998-September 1999

A Double-Blind, Randomized, Placebo-Controlled Study of RO-64-0796 in the Treatment of Children with Influenza (Protocol No. WV 15758)

Principal Investigator: Myron J. Levin, MD

Source: Roche Pharmaceutical Research

Amount: \$49,670

Term: October 1998-September 1999

Pilot Study of the Safety, Tolerability and Immunogenicity of a Live Attenuated Varicella Vaccine (VARIVAX™) in Asthmatic Subjects 12 Months to 18 Years of Age Who Are Receiving Chronic Inhaled Corticosteroids

Principal Investigator: Myron J. Levin, MD

Source: Merck Sharp and Dohme Research Laboratories

Amount: \$202,900

Term: October 1998-September 1999

National Institute of Child Health and Human Development Pediatric and Perinatal HIV Clinical Trials

Principal Investigator: Myron J. Levin, MD

Co-Investigator: Elizabeth J. McFarland, MD

Source: Westat National Institute of Child and Human Development - N01-HD-3-3162

Amount: \$3,138,000

Term: September 1996-October 2000

Trial of Varicella Vaccine for the Prevention of Herpes Zoster

and its Complications (Protocol No. 403)

Principal Investigator: Myron J. Levin, MD

Source: National Institute of Allergy and Infectious Disease,
Veterans Administration

Amount: \$1,532,185

Term: December 1998-December 2004

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Pilot Study to Assess the Safety of Live, Attenuated Varicella-Zoster Vaccine Given Concomitantly with Recombinant Human Interleukin-12 (rhIL-12) in Healthy Adults 60 to 79 Years of Age

Principal Investigator: Myron J. Levin, MD

Source: Genetics Institute

Amount: \$96,000

Term: April 1998-March 1999

Phase II Dose Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 and Phase I Study to Evaluate the Safety and Immunogenicity of MEDI-517 in Healthy Adults Who Are HPV-16 or HPV-18 DNA Positive

Principal Investigator: Myron J. Levin, MD

Source: MedImmune, Inc.

Amount: \$157,047

Term: November 1999-October 2000

Study of Immunogenicity of Pilot Manufacturing Material of HPV 16 Virus-Like Particles (VLP) Vaccine in 18-25 Year Old Women

Principal Investigator: Myron J. Levin, MD

Source: Merck Sharp and Dohme Research Laboratories

Amount: \$94,320

Term: October 1998-September 2000

Pilot Study of the Safety, Tolerability and Immunogenicity of a Live Attenuated Varicella Vaccine (VARIVAXTM) in Asthmatic Subjects 12 Months to 18 Years of Age Who Are Receiving Chronic Inhaled Corticosteroids

Principal Investigator: Myron J. Levin, MD

Source: Merck Sharp and Dohme Research Laboratories

Amount: \$202,900

Term: September 1999-October 2000

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccine (gD2t) with MPL and its Efficacy to Prevent Genital Herpes Disease in Healthy HSV Positive or Negative Consorts of Subjects with Genital Herpes Disease (Protocol No. 017)

Principal Investigator: Myron J. Levin, MD

Source: SmithKline Beecham Biologicals

Amount: \$96,000

Term: July 1996-June 1999

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of SmithKline Beecham Biologicals' Herpes Simplex candidate vaccine (gD2t) with MPL to Prevent Genital Herpes Disease in Healthy Consorts of Subjects with

Genital Herpes Disease (Protocol No. 007)

Principal Investigator: Myron J. Levin, MD

Source: SmithKline Beecham Biologicals

Amount: \$143,098

Term: July 1996-June 1999

Ryan White Title IV HIV Program

Principal Investigator: Myron J. Levin, MD

Co-Investigator: Adriana Weinberg, MD

Source: National Institute of Child Health and Human Development

Amount: \$30,400/yr

Term: August 1995-July 2001

Expansion of Pediatric AIDS Clinical Trials Unit

Principal Investigator: Myron J. Levin, MD

Co-Investigator: Adriana Weinberg, MD

Source: National Institute of Child Health and Human Development

Amount: \$21,715/yr

Term: November 1995-October 2001

Ryan White Title I Funds for HIV Care

Principal Investigator: Elizabeth J. McFarland, MD

Source: Mayor's Office of HIV Resources

Amount: \$35,500

Term: March 1998-February 1999

V-beta Repertoire Assay Development

Principal Investigator: Elizabeth J. McFarland, MD

Source: Social and Scientific Systems, Inc.

Amount: \$25,000

Term: April 1998-April 1999

Mechanisms Leading to Decline of HIV-Specific CTL

Principal Investigator: Elizabeth J. McFarland, MD

Source: National Institutes of Health, National Institute of Allergy and Infectious Diseases

Amount: \$659,007

Term: August 1998-July 2001

Children's Hospital Immunodeficiency Program, Ryan White Title I Formula Fund

Principal Investigator: Ann-Christine Nyquist, MD, MSPH

Source: Health Resources and Services Administration, Ryan White Title I

Amount: \$3,763

Term: March 1998-February 1999

Children's Hospital Immunodeficiency Program, Ryan White Title I Formula Fund

Principal Investigator: Ann-Christine Nyquist, MD, MSPH

Source: Health Resources and Services Administration, Ryan White Title I

Amount: \$46,450

Term: March 2000-March 2001

CHIP Youth Project

Principal Investigator: Ann-Christine Nyquist, MD, MSPH

Source: Gill Foundation

Amount: \$18,500

Term: January 1998-January 1999

Natural History of Pre-Diabetic Autoimmunity - Lab

Principal Investigator: Harley A. Rotbart, MD

Source: National Institutes of Health

Amount: \$15,000

Term: 1998-1999

Enterovirus Research

Principal Investigator: Harley A. Rotbart, MD

Source: ViroPharma Research

Amount: \$73,000

Term: 1998-1999

Enterovirus Research

Co-Principal Investigator: Harley A. Rotbart, MD

Source: Pharmacia and Upjohn

Amount: \$55,000

Term: 1998-1999

Enterovirus Research

Principal Investigator: Harley A. Rotbart, MD

Source: Specialty Laboratories

Amount: \$24,000

Term: 1998-1999

Enterovirus Research

Principal Investigator: Harley A. Rotbart, MD

Source: The Children's Hospital, Denver

Amount: \$25,000

Term: 1998-1999

Pediatric Pharmacology Research Unit Network

Principal Investigator: Stanley J. Szeffler, MD

Co-Principal Investigators: Harley A. Rotbart, MD, and Mark J. Abzug, MD

Source: National Institutes of Health

Amount: \$1,364,175

Term: January 1999-December 2003

Pediatric AIDS Clinical Trials Group CMV Laboratory

Principal Investigator: Adriana Weinberg, MD

Source: National Institute of Allergy and Infectious Disease

Amount: \$37,500/yr

Term: 1997-2000

Pediatric AIDS Clinical Trials Group Immunology Core Laboratory

Principal Investigators: Adriana Weinberg, MD, and Elizabeth J. McFarland, MD

Source: National Institute of Child Health and Human Development

Amount: \$350,000/yr

Term: 1997-2001

Pediatric AIDS Clinical Trials Group CMV Immunity Laboratory

Principal Investigator: Adriana Weinberg, MD

Source: National Institute of Allergy and Infectious Disease

Amount: \$18,120

Term: 1998-2000

Topical Treatment of HSV

Principal Investigator: Adriana Weinberg, MD

Source: SmithKline Beecham

Amount: \$450,000

Term: 1999-2001

Varicella Zoster Immunity in AIDS

Principal Investigator: Adriana Weinberg, MD

Source: National Institutes of Health

Amount: \$29,000

Term: 1998-2000

Quantitative CMV PCR

Principal Investigator: Adriana Weinberg, MD

Source: National Institute of Allergy and Infectious Disease

Amount: \$92,000

Term: 1999-2002

[Top of Page](#)

Copyright 2001

[The Children's Hospital](#)

[University of Colorado Health Sciences Center](#)

[Legal Notices](#)

Last modified: 11-14-2005

[Search](#)

[UCHSC/TCH](#)

[About this Site](#)

[Mail Webmaster](#)